Literature DB >> 21381151

The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells.

Christopher J Bissonnette1, Ljuba Lyass, Bula J Bhattacharyya, Abdelhak Belmadani, Richard J Miller, John A Kessler.   

Abstract

An early substantial loss of basal forebrain cholinergic neurons (BFCN) is a constant feature of Alzheimer's disease and is associated with deficits in spatial learning and memory. The ability to selectively control the differentiation of human embryonic stem cells (hESCs) into BFCN would be a significant step toward a cell replacement therapy. We demonstrate here a method for the derivation of a predominantly pure population of BFCN from hESC cells using diffusible ligands present in the forebrain at developmentally relevant time periods. Overexpression of two relevant human transcription factors in hESC-derived neural progenitors also generates BFCN. These neurons express only those markers characteristic of BFCN, generate action potentials, and form functional cholinergic synapses in murine hippocampal slice cultures. siRNA-mediated knockdown of the transcription factors blocks BFCN generation by the diffusible ligands, clearly demonstrating the factors both necessary and sufficient for the controlled derivation of this neuronal population. The ability to selectively control the differentiation of hESCs into BFCN is a significant step both for understanding mechanisms regulating BFCN lineage commitment and for the development of both cell transplant-mediated therapeutic interventions for Alzheimer's disease and high-throughput screening for agents that promote BFCN survival.
Copyright © 2011 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21381151      PMCID: PMC3107131          DOI: 10.1002/stem.626

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  53 in total

1.  Mnemonic deficits in animals depend upon the degree of cholinergic deficit and task complexity.

Authors:  Donald P Pizzo; Leon J Thal; Jürgen Winkler
Journal:  Exp Neurol       Date:  2002-09       Impact factor: 5.330

2.  Lesions of the Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning.

Authors:  James M Conner; Andrew Culberson; Christine Packowski; Andrea A Chiba; Mark H Tuszynski
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

3.  Grafts of fetal septal cells after cholinergic immunotoxic denervation of the hippocampus: a functional dissociation between dorsal and ventral implantation sites.

Authors:  J-C Cassel; M Gaurivaud; C Lazarus; F Bertrand; R Galani; H Jeltsch
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

4.  Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum.

Authors:  Marsel Mesulam; Pamela Shaw; Deborah Mash; Sandra Weintraub
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

5.  The LIM-homeobox gene Lhx8 is required for the development of many cholinergic neurons in the mouse forebrain.

Authors:  Yangu Zhao; Oscar Marín; Edit Hermesz; Aaron Powell; Nuria Flames; Miklós Palkovits; John L R Rubenstein; Heiner Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-10       Impact factor: 11.205

6.  Unilateral lesions of the cholinergic basal forebrain and fornix in one hemisphere and inferior temporal cortex in the opposite hemisphere produce severe learning impairments in rhesus monkeys.

Authors:  A Easton; R M Ridley; H F Baker; D Gaffan
Journal:  Cereb Cortex       Date:  2002-07       Impact factor: 5.357

7.  Augmentation of plasticity of the central auditory system by the basal forebrain and/or somatosensory cortex.

Authors:  Xiaofeng Ma; Nobuo Suga
Journal:  J Neurophysiol       Date:  2003-01       Impact factor: 2.714

8.  Decreased neurogenesis after cholinergic forebrain lesion in the adult rat.

Authors:  Christiana M Cooper-Kuhn; Jürgen Winkler; H Georg Kuhn
Journal:  J Neurosci Res       Date:  2004-07-15       Impact factor: 4.164

9.  Progressive accumulation of epigenetic heterogeneity during human ES cell culture.

Authors:  Borko Tanasijevic; Bo Dai; Toshihiko Ezashi; Kimberly Livingston; R Michael Roberts; Theodore P Rasmussen
Journal:  Epigenetics       Date:  2009-07-15       Impact factor: 4.528

Review 10.  Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction.

Authors:  Elliott J Mufson; Stephen D Ginsberg; Milos D Ikonomovic; Steven T DeKosky
Journal:  J Chem Neuroanat       Date:  2003-12       Impact factor: 3.052

View more
  78 in total

Review 1.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

2.  Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.

Authors:  Stephanie L Adams; Laurent Benayoun; Kathy Tilton; Tiffany J Mellott; Sudha Seshadri; Jan Krzysztof Blusztajn; Ivana Delalle
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Ketamine induces toxicity in human neurons differentiated from embryonic stem cells via mitochondrial apoptosis pathway.

Authors:  Zeljko J Bosnjak; Yasheng Yan; Scott Canfield; Maria Y Muravyeva; Chika Kikuchi; Clive W Wells; John A Corbett; Xiaowen Bai
Journal:  Curr Drug Saf       Date:  2012-04

4.  Human pluripotent stem cell differentiation into authentic striatal projection neurons.

Authors:  Alessia Delli Carri; Marco Onorati; Valentina Castiglioni; Andrea Faedo; Stefano Camnasio; Mauro Toselli; Gerardo Biella; Elena Cattaneo
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

Review 5.  Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.

Authors:  Priya Srikanth; Tracy L Young-Pearse
Journal:  J Neurogenet       Date:  2014-03-17       Impact factor: 1.250

6.  Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease.

Authors:  Tandis Vazin; K Aurelia Ball; Hui Lu; Hyungju Park; Yasaman Ataeijannati; Teresa Head-Gordon; Mu-ming Poo; David V Schaffer
Journal:  Neurobiol Dis       Date:  2013-09-18       Impact factor: 5.996

7.  Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers.

Authors:  Mariana A de Godoy; Leonardo M Saraiva; Luiza R P de Carvalho; Andreia Vasconcelos-Dos-Santos; Hellen J V Beiral; Alane Bernardo Ramos; Livian R de Paula Silva; Renata B Leal; Victor H S Monteiro; Carolina V Braga; Carlla A de Araujo-Silva; Leandro C Sinis; Victor Bodart-Santos; Tais Hanae Kasai-Brunswick; Carolina de Lima Alcantara; Ana Paula C A Lima; Narcisa L da Cunha-E Silva; Antonio Galina; Adalberto Vieyra; Fernanda G De Felice; Rosalia Mendez-Otero; Sergio T Ferreira
Journal:  J Biol Chem       Date:  2017-12-28       Impact factor: 5.157

8.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 9.  Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience.

Authors:  Jerome Mertens; Maria C Marchetto; Cedric Bardy; Fred H Gage
Journal:  Nat Rev Neurosci       Date:  2016-05-19       Impact factor: 34.870

10.  Derivation and isolation of NKX2.1-positive basal forebrain progenitors from human embryonic stem cells.

Authors:  Noélle D Germain; Erin C Banda; Sandy Becker; Janice R Naegele; Laura B Grabel
Journal:  Stem Cells Dev       Date:  2013-03-05       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.